Preventing onset of psychosis: Identification of population at risk and early treatment strategy;Prevence vzniku psychotického onemocnění: Identifikace ohrožených jedinců a možnosti včasné terapeutické intervence

Psychiatrie

Volumn 9, Issue SUPPL. 3, 2005, Pages 105-108

  Mohr, Pavel ^a,b,c   Rodriguez, Mabel ^a,b,d   Seifertová, Dagmar ^a,b,c  

^a FCentrum Neuropsychiatrických Studií   (Czech Republic)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d Charles University   (Czech Republic)

Author keywords

Early treatment; Prevention; Prodromes; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

COGNITIVE THERAPY; CONFERENCE PAPER; CONSENSUS; DISEASE SEVERITY; HIGH RISK POPULATION; HUMAN; NEUROPSYCHOLOGY; PSYCHOSIS; SCHIZOPHRENIA;

EID: 25444525476     PISSN: 12117579     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (47)

1. Amminger GP, Edwards J, Brewer WJ, Harrigan S, McGorry PD. Duration of untreated psychosis and cognitive deterioration in first-episode schizophrenia. Schizophr Res 2002; 54:223-230.
2. Berrios GE, Brook P. Visual hallucinations and sensory delusions in the elderly. Br J Psychiatry 1984; 144:662-664.
3. Brewer WJ, Francey SM, Wood SJ, Jackson HJ, Pantelis C, Phillips LJ, Yung AR, Anderson VA, McGorry PD. Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am J Psychiatry 2005; 162:71-78.
4. Candilis PJ. Early intervention in schizophrenia: three frameworks for guiding ethical inquiry. Psychopharmacology 2003; 171:75-80.
5. Cannon M, Caspi A, Moffitt TE, Harrington H, Taylor A, Murray RM, Poulton R. Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. Arch Gen Psychiatry 2002a; 59:449-456.
6. Cannon TD, Huttunen MO, Dahlstrom M, Larmo I, Rasanen P, Juriloo A. Antipsychotic drug treatment in the prodromal phase of schizophrenia. Am J Psychiatry 2002b; 159:1230-1232.
7. Cornblatt BA, Lencz T, Kane JM. Treatment of the schizophrenia prodrome: is it presently ethical? Schizophr Res 2001; 51:31-38.
8. DeGrazia D. Ethical issues in early-intervention clinical trials involving minors at risk for schizophrenia. Schizophr Res 2001; 51(1):77-86.
9. Erlenmeyer-Kimling L, Rock D, Roberts SA, Janal M, Kestenbaum C, Cornblatt B, Adamo UH, Gottesman II. Attention, memory, and motor skills as childhood predictors of schizophrenia-related psychoses: the New York High-Risk Project. Am J Psychiatry 2000; 157:1416-1422.
10. Escher S, Romme M, Buiks A, Delespaul P, Van Os J. Independent course of childhood auditory hallucinations: a sequential 3-year follow-up study. Br J Psychiatry 2002; 181(suppl. 43):10-18.
11. Fernandez A, Lichtshein G, Vieweg W, Victor R. The Charles Bonnet syndrome: a review. J Nerv Ment Dis 1997; 185:195-200.
12. Friis S, Larsen TK, Melle I, Opjordsmoen S, Johannessen JO, Haahr U, Simonsen E, Rund BR, Vaglum P, McGlashan T. Methodological pitfalls in early detection studies - the NAPE Lecture 2002. Nordic Association for Psychiatric Epidemiology. Acta Psychiatr Scand 2003; 107:3-9.
13. Hawkins KA, Addington J, Keefe RS, Christensen B, Perkins DO, Zipurksy R, Woods SW, Miller TJ, Marquez E, Breier A, McGlashan TH. Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophr Res 2004; 67:115-122.
14. Johns LC, Cannon M, Singleton N, Murray RM, Farrell M, Brugha T, Bebbington P, Jenkins R, Meltzer H. Prevalence and correlates of self-reported psychotic symptoms in the British population. Br J Psychiatry 2004; 185:298-305.
15. Knowles L, Sharma T. Identifying vulnerability markers in prodromal patients: a step in the right direction for schizophrenia prevention. CNS Spectr 2004; 9:595-602.
16. Loebel AD, Lieberman JA, Alvir JM, et al. Duration of psychosis and outcome in first-episode of schizophrenia. Am J Psychiatry 1992; 149:1183-1188.
17. Maier W, Cornblatt BA, Merikangas KR. Transition to schizophrenia and related disorders: toward a taxonomy of risk. Schizophr Bull 2003; 29:693-701.
18. McGlashan TH. Commentary: progress, issues, and implications of prodromal research: an inside view. Schizophr Bull 2003; 29:851-858.
19. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, Hawkins KA, Hoffman R, Lindborg S, Tohen M, Breier A. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr Res 2003; 61:7-18.
20. McGlashan TH, Zipursky RB, Perkins D, Addington J, Woods SW, Miller TJ, Lindborg S. Olanzapine vs. Placebo for prodromal schizophrenia. Schizophr Res 2004a; 67(Suppl. 1):6.
21. McGlashan TH, Zipursky RB, Perkins D, Addington J. Olanzapine for treatment of the schizophrenia prodrome: 2-year results of a randomized placebo-controlled study. Schizophr Res 2004b; 67(Suppl. 1):164.
22. McGorry PD. The detection and optimal management of early psychosis. In: Comprehensive care of schizophrenia, Eds.: Lieberman JJA, Murray RM, London: Martin Dunitz 2001; 153-166.
23. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, McDonald T, Blair A, Adlard S, Jackson H. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59:921-928.
24. Mertin P, Hartwig S. Auditory hallucinations in nonpsychotic children: diagnostic considerations. Child Adolescent Mental Health 2004; 9:9-14.
25. Miller TJ, Zipursky RB, Perkins D, Addington J, Woods SW, Hawkins KA, Hoffman R, Preda A, Epstein I, Addington D, Lindborg S, Marquez E, Tohen M, Breier A, McGlashan TH. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophr Res 2003; 61:19-30.
26. Mojtabai R, Malaspina D, Susser E. The concept of population prevention: application to schizophrenia. Schizophr Bull 2003; 29:791-801.
27. Morrison AP, Bentall RP, French P, Walford L, Kilcommons A, Knight A, Kreutz M, Lewis SW. Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high-risk individuals. Study design and interim analysis of transition rate and psychological risk factors. Br J Psychiatry 2002; 43(Suppl. Sep):78-84.
28. Olfson M, Lewis-Fernandez R, Weissman MM, Feder A, Gameroff MJ, Pilowsky D, Fuentes M. Psychotic symptoms in an urban general medicine practice. Am J Psychiatry 2002; 159:1412-1419.
29. Östling S, Skoog I. Psychotic symptoms and paranoid ideation in a nondemented population-based sample of the very old. Arch Gen Psychiatry 2002; 59:53-59.
30. Pantelis C, Velakoulis D, McGorry PD, Wood SJ, Suckling J, Phillips LJ, Yung AR, Bullmore ET, Brewer W, Soulsby B, Desmond P, McGuire PK. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003a; 361(9354):281-288.
31. Pantelis C, Yucel M, Wood SJ, McGorry PD, Velakoulis D. Early and late neurodevelopmental disturbances in schizophrenia and their functional consequences. Aust N Z J Psychiatry 2003; 37:399-406.
32. Romme M, Escher S. Hearing Voices Schizophr Bull 1989; 15:209-216.
33. Schaffner KF, McGorry PD. Preventing severe mental illnesses - new prospects and ethical challenges. Schizophr Res 2001; 51:3-15.
34. Strauss JS. Hallucinations and delusions as points on continua function. Rating scale evidence. Arch Gen Psychiatry 1969; 21:581-586.
35. Teunisse RJ, Cruysberg JR, Hoefnagels, WH, Verbeek AL, Zitman FG. Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome: CBS Lancet 1996; 347:794-797.
36. Tien AY. Distributions of hallucinations in the population. Soc Psychiatry Psychiatr Epidemiol 1991; 26:287-292.
37. Tsuang MT, Stone WS, Faraone SV. Towards the prevention schizophrenia. Biol Psychiatry 2000; 48:349-356.
38. Tsuang MT, Stone WS, Faraone SV. Understanding predisposition to schizophrenia: toward intervention and prevention. Can J Psychiatry 2002; 47:518-526.
39. Van Os J, Hanssen M, Bijl RV, Ravelli AR. Strauss (1969) revisited: a psychosis continuum in the general population? Schizophr Res 2000; 45:11-20.
40. Van Os J, Hanssen M, Bijl RV, Vollebergh W. Prevalence of psychotic disorder and community level of psychotic symptoms an urban-rural comparison Arch Gen Psychiatry 2001; 58:663-668.
41. Velakoulis D, Wood SJ, Smith DJ, Soulsby B, Brewer W, Leeton L, Desmond P, Suckling J, Bullmore ET, McGuire PK, Pantelis C. Increased duration of illness is associated with reduced volume in right medial temporal/anterior cingulate grey matter in patients with chronic schizophrenia. Schizophr Res 2002; 57:43-49.
42. Verdoux H, Cougnard A. The early detection and treatment controversy in schizophrenia research. Curr Opin Psychiatry 2003; 16:175-179.
43. Wood SJ, Yucel M, Yung AR, Berger GE, Velakoulis D, Pantelis C. The transition to psychosis: risk factors and brain changes. Epidemiol Psychiatr Soc 2004; 13:137-140.
44. Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, Hawkins KA, Marquez E, Lindborg SR, Tohen M, McGlashan TM. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry 2003; 54:453-464.
45. Yoshizumi T, Murase S, Honjo S, Kaneko H, Murakami T. Hallucinatory experiences in a community sample of Japanese children. J Am Acad Child Adol Psychiatry 2004; 43:1030-1036.
46. Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA, Hallgren M, McGorry PD. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res 2003; 60:21-32.
47. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra hign-risk group: psychopathology and clinical features. Schizophr Res 2004; 67:131-142.